The findings suggest clinicians don’t need to be as aggressive in lowering BP in this population, at least early after ...

New concepts in device therapy for advanced heart failure presented in early reports ...

In 2006, Steve Pitkin suffered a serious heart attack while hiking above Salt Lake City with his daughter. The main artery in Pitkin’s heart was completely blocked, leaving 70% of his left ventricle ...

Female recipients of a left ventricular assist device tend to have worse clinical outcomes compared to their male counterparts, according to a study in Circulation: Heart Failure from researchers at ...

Outcomes and expenses were similar with transplant and elective LVAD, but urgent LVAD after ECMO fared much worse.

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, has announced a collaborative effort with Abbott (NYSE:ABT) to advance this novel anticoagulant for ...

Please provide your email address to receive an email when new articles are posted on . ANAHEIM, Calif. — A decision-support intervention was associated with improved decision quality among candidates ...

Two years ago, on a family skiing trip to Colorado, Toby Wise was struggling to keep up. Wise, 45, had always been in good health, played football in high school and played in a softball league and a ...

Beware a maculopapular rash years after left ventricular assist device (LVAD) implantation, according to clinicians describing the phenomenon of LVAD vasculitis in a case series. Three cases of LVAD ...

Heart disease can leave a patient tied to a bed or a hospital room waiting on life, instead of living it. However, medical advances are giving people with heart disease a chance to live more freely - ...

The advanced heart failure team at Virtua Our Lady of Lourdes Hospital in Camden has successfully performed the health system’s first left ventricular assist device (LVAD) implantation. LVADs are ...

PONTE VEDRA, Fla., March 04, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular ...